Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax

Fineline Cube Jun 29, 2026
Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Fineline Cube Jun 24, 2026
Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Fineline Cube Jun 24, 2026
Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Fineline Cube Jun 24, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

AbbVie’s SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older

Fineline Cube Jun 29, 2026
Company Drug

Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval

Fineline Cube Jun 29, 2026
Company Deals

Sinopharm Partners with Fudan University to Establish National Innovation Platform

Fineline Cube May 8, 2023

China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strategic partnership with Fudan...

Company Drug

Reistone Biopharma’s Edralbrutinib Earns Orphan Drug Designation for NMOSD from US FDA

Fineline Cube May 8, 2023

Reistone Biopharma Co., Ltd, a company incubated by Hengrui Medicine with an investment of USD...

Company Deals

Lingyi Biotechnology Secures RMB 100 Million in Series A Funding for Gene Therapy Pipeline

Fineline Cube May 6, 2023

China-based gene therapy developer Lingyi Biotechnology Co., Ltd has reportedly raised close to RMB 100...

Company Drug

Henlius Biotech’s HLX26 and HaiSiZhuang Combo for NSCLC Gets NMPA Phase II Approval

Fineline Cube May 6, 2023

Shanghai Henlius Biotech (HKG: 2696) has announced that it has received approval from the National...

Company Deals

Shanghai Junshi Biosciences Inks Exclusive License Deal with Dr. Reddy’s Laboratories for Tuoyi

Fineline Cube May 6, 2023

Shanghai Junshi Biosciences Co., Ltd (SHA: 688180), a China-based biotechnology firm, has announced an exclusive...

Company Deals

Sinopharm Partners with Shenzhen to Boost High-End Medical Device and Pharmaceutical Innovation

Fineline Cube May 6, 2023

China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strategic partnership with Shenzhen...

Company Deals

XtalPi Inc. and China Pharmaceutical University Launch Joint AI Research Center in China

Fineline Cube May 6, 2023

Sino-US artificial intelligence (AI) firm XtalPi Inc. has joined forces with China Pharmaceutical University (CPU)...

Company Medical Device

Omega Medical Imaging’s Soteria.AI Receives FDA Approval for Interventional Cardiology

Fineline Cube May 6, 2023

US-based medical technology firm Omega Medical Imaging has received marketing approval from the US Food...

Policy / Regulatory

NMPA Extends Public Feedback Period for ‘Drug Standardization Management Measures’ in China

Fineline Cube May 6, 2023

The National Medical Products Administration (NMPA) in China has announced an extension to the public...

Company Deals

Hasten Biopharm Acquires Commercial Rights to Rocephin in China from Roche

Fineline Cube May 6, 2023

China-based Hasten Biopharmaceutical Co., Ltd has announced the acquisition of the commercial rights in China...

Company

Mindray Reports Strong YOY Growth in 2022 and Q1 2023 Financial Results

Fineline Cube May 6, 2023

China-based medical device firm Mindray (SHE: 300760) has released its financial reports for the year...

Policy / Regulatory

Anhui and Qinghai Provinces Update BMI Chronic Disease Drug Lists for Outpatient Reimbursement

Fineline Cube May 6, 2023

The healthcare security bureaus of Anhui and Qinghai provinces in China have separately released notifications...

Company Drug

Huadong Medicine’s Mefatinib Poised for Breakthrough Therapy Designation by CDE

Fineline Cube May 6, 2023

The Center for Drug Evaluation (CDE) website indicates that China-based Huadong Medicine Co., Ltd (SHE:...

Company Deals

VivaVision Biotech Secures Over RMB 100 Million in Series D2 Financing for Ophthalmology Pipeline Expansion

Fineline Cube May 5, 2023

China’s VivaVision Biotech Inc. has announced the successful completion of its Series D2 financing round,...

Company Drug

Yantai Dongcheng Pharma’s 177Lu-LNC1003 Cleared for US FDA Phase I Study

Fineline Cube May 5, 2023

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that it has received...

Company Drug

ABM Therapeutics’ ABM-168 Begins Phase I Dosing in the US for Advanced Solid Tumors

Fineline Cube May 5, 2023

Shanghai-based ABM Therapeutics, Inc. has announced the commencement of the first patient enrollment and dosing...

Company Deals

Kangrui Health Partners with West China Second University Hospital for Pediatric Care Innovation

Fineline Cube May 5, 2023

Kangrui Health, a leading data and intelligence application company based in Beijing, has entered into...

Policy / Regulatory R&D

China’s CDE Releases 69th Batch of Generic Chemical Reference Preparations for Public Review

Fineline Cube May 5, 2023

The Center for Drug Evaluation (CDE) in China has released the 69th batch of chemical...

Company Drug

Innovent Biologics’ GFH925 Earns Breakthrough Therapy Designation for KRASG12C CRC Treatment

Fineline Cube May 5, 2023

The Center for Drug Evaluation (CDE) website indicates that China-based Innovent Biologics’ (HKG: 1801) Category...

Company Drug

CARsgen Therapeutics’ AB011 and Tecentriq Combo Gets NMPA Approval for Gastric Cancer Treatment

Fineline Cube May 5, 2023

China-based chimeric antigen receptor (CAR)-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced...

Posts pagination

1 … 551 552 553 … 688

Recent updates

  • AbbVie’s SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older
  • Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval
  • Eli Lilly’s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use
  • Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax
  • J&J’s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AbbVie’s SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older

Company Drug

Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval

Company Drug

Eli Lilly’s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use

Company Deals

Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.